QUINACRINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C23H30ClN3O.2ClH.2H2O
Molecular Weight	508.909
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.Cl.Cl.CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC3=C1C=CC(Cl)=C3

InChI

InChIKey=RZFNKJVCPDLQQA-UHFFFAOYSA-N

InChI=1S/C23H30ClN3O.2ClH.2H2O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23;;;;/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26);2*1H;2*1H2

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C23H30ClN3O
Molecular Weight	399.957
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mmx/mepacrine.html

Quinacrine was initially developed as an anti-malarial drug marketed under the name Atabrine. Also it was approved for the teratment of ascites, however it was wothdrawn for both indication in 1995 and 2003, respectively. The drug is also used for the treatment of giardiasis, lupus, rheumatoid arthritis, refractory pulmonary effusion and pneumothorax, induce female sterilization etc. Proposed mechanisms of action include DNA intercalation interference with RNA transcription and translation, inhibition of succinate oxidation interference with electron transport, inhibition of cholinesterase, and inhibitor of phospholipase.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Malaria 95 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Preventing	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis.
Ascites due to various cancers 3 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Primary	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis. Launch Date 1964
Giardiasis 12 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Curative	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis.
Cestodiasis 3 Sources: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm486146.pdf	Curative	Withdrawn	Atabrine Approved Use For the treatment of ascites due to various cancers, malaria, cestodiasis and giardiasis.

Doses

Dose	Population	Adverse events
300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	Other AEs: Distress gastrointestinal, Blood alkaline phosphatase abnormal... Other AEs: Distress gastrointestinal (serious, 1 patient) Blood alkaline phosphatase abnormal (3 patients) ALT increased (3 patients) Aspartate aminotransferase abnormal (3 patients) GGTP abnormal (3 patients) Seizure (serious, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/24122181

AEs

AE	Significance	Dose	Population
ALT increased	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Aspartate aminotransferase abnormal	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Blood alkaline phosphatase abnormal	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
GGTP abnormal	3 patients	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Distress gastrointestinal	serious, 1 patient	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181
Seizure	serious, 1 patient	300 mg 1 times / day multiple, oral Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24122181	unhealthy, 60.5 years (range: 40–75 years) n = 23 Health Status: unhealthy Condition: sporadic Creutzfeldt-Jakob disease Age Group: 60.5 years (range: 40–75 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/24122181

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C19 1478	CYP3A5 395 CYP3A7 110 CYP1A1 349 CYP1A2 1054 CYP4A11 119 CYP2B6 664 CYP2C8 693 CYP2C19 991 P-gp 1537

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1891	inhibitor 3277 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 0.013 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 3.96 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 6.66 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 8.66 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://aac.asm.org/content/63/9/e01142-19	yes [IC50 >50 uM]

Drug as victim

Target	Modality	Activity
CYP1A1 349	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP3A7 110	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
CYP4A11 119	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	minor
P-gp 1537	substrate 3367 Sources: https://aac.asm.org/content/63/9/e01142-19	unlikely
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	yes
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16581945/	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-049679	http://www.3bsc.com/index/pro_info.php?id=87256
AA Blocks	AA0035HC	https://www.aablocks.com/goods/Goods/detail?id=AA0035HC
AHH Chemical co.,ltd	MT-22110	http://www.ahhchemical.com/product/MT-22110.html
Aaron Chemicals	AR003694	http://www.aaronchem.com/69-05-6
AbMole Bioscience	M5132	http://www.abmole.com/products/quinacrine-dihydrochloride-dihydrate.html
AbMole Bioscience	M3183	http://www.abmole.com/products/quinacrine-dihydrochloride.html
Achemtek	0102-012689	http://www.achemtek.com/69-05-6
Achemtek	0102-012688	http://www.achemtek.com/83-89-6
Ambeed	A266175	https://www.ambeed.com/products/69-05-6.html
Ambinter	Amb2198111	http://www.ambinter.com/reference/2198111
Ambinter	Amb2444874	http://www.ambinter.com/reference/2444874
Ark Pharm	AK01050742	http://www.arkpharminc.com/products/69-05-6.html
Aronis	ARONIS014439	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=15606
Aurora Fine Chemicals LLC	A13.140.424	http://online.aurorafinechemicals.com/info?ID=A13.140.424
Aurora Fine Chemicals LLC	A17.866.451	http://online.aurorafinechemicals.com/info?ID=A17.866.451
Aurora Fine Chemicals LLC	A17.943.708	http://online.aurorafinechemicals.com/info?ID=A17.943.708
Aurora Fine Chemicals LLC	K01.172.209	http://online.aurorafinechemicals.com/info?ID=K01.172.209
Aurora Fine Chemicals LLC	K02.127.796	http://online.aurorafinechemicals.com/info?ID=K02.127.796
BLD Pharm	BD149994	http://www.bldpharm.com/products/69-05-6.html
BOC Sciences	6151-30-0	https://www.bocsci.com/mepacrine-hcl-cas-6151-30-0-item-73187.html
BOC Sciences	130-42-7	https://www.bocsci.com/n4-6-chloro-2-methoxyacridin-9-yl-n1-n1-diethylpentane-1-4-diamine-cas-130-42-7-item-83462.html
BioCrick	BCC4709	http://www.biocrick.com/Quinacrine-2HCl-BCC4709.html
CSNpharm	CSN11815	https://www.csnpharm.com/products/quinacrine-dihydrochloride.html
Chem Scene	CS-0027605	http://www.chemscene.com/6151-30-0.html
Chem Scene	CS-4590	http://www.chemscene.com/69-05-6.html
ChemMol	30115906	http://www.chemmol.com/chemmol/30115906.html
ChemShuttle	151922	http://www.chemshuttle.com/catalogsearch/result/?q=69-05-6&cat=
Chemenu	CM110305	http://www.chemenu.com/products/CM110305
Chemspace	CSSB00020573737	https://chem-space.com/CSSB00020573737
Chemspace	CSSB00020643237	https://chem-space.com/CSSB00020643237
DC Chemicals	DC22483	http://www.dcchemicals.com/product_show-DC22483.html
Debye Scientific	DB-055218	http://www.debyesci.com/cas_69-05-6.html
Enamine	Z31251611	https://www.enaminestore.com/catalog/Z31251611
Finetech	FT-0674264	http://www.finetechnology-ind.com/prod/detail/pub/1189976-99-5.html
Finetech	FT-0698684	http://www.finetechnology-ind.com/prod/detail/pub/6151-30-0.html
Finetech	FT-0631298	http://www.finetechnology-ind.com/prod/detail/pub/69-05-6.html
Finetech	FT-0778222	https://www.finetechnology-ind.com/prod/detail/pub/83-89-6.html
Hairui	HR141775	http://www.hairuichem.com/en/product/6151-30-0.html
LGC Standards	LGCFOR1695.00	https://www.lgcstandards.com/US/en/p/LGCFOR1695.00
LGC Standards	MM1695.00	https://www.lgcstandards.com/US/en/p/MM1695.00
Lab Network	LN00194413	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00194413
Lab Network	LN00438137	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00438137
MedChem Express	HY-13735A	https://www.medchemexpress.com/Quinacrine-dihydrochloride.html
MedChem Express	HY-13735B	https://www.medchemexpress.com/quinacrine-hydrochloride-hydrate.html
MolMall	20785	http://www.molmall.net/product/20785
MolPort	MolPort-001-739-072	https://www.molport.com/shop/molecule-link/MolPort-001-739-072
MolPort	MolPort-003-665-492	https://www.molport.com/shop/molecule-link/MolPort-003-665-492
MolPort	MolPort-018-655-037	https://www.molport.com/shop/molecule-link/MolPort-018-655-037
Molcore	MC563510	https://www.molcore.com/product/6151-30-0
Molcore	MC567398	https://www.molcore.com/product/69-05-6
Molcore	MC573483	https://www.molcore.com/product/83-89-6
MuseChem	A000170	https://www.musechem.com/product/A000170.html
MuseChem	M010474	https://www.musechem.com/product/M010474.html
MuseChem	M067091	https://www.musechem.com/product/M067091.html
Selleck Chemicals	S4255	http://www.selleckchem.com/products/quinacrine-2hcl.html
Selleck Chemicals	S5435	http://www.selleckchem.com/products/quinacrine-dihydrochloride-dihydrate.html
Sigma-Aldrich	CDS020709_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/cds020709?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PH001921_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph001921
Sigma-Aldrich	Q3251_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/q3251?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S011909	http://www.sinfoobiotech.com/product/1015307
Smolecule	S534971	http://www.smolecule.com/products/s534971
Smolecule	S548903	http://www.smolecule.com/products/s548903
TCI (Tokyo Chemical Industry)	Q0056	http://www.tcichemicals.com/eshop/en/us/commodity/Q0056/index.html
THE BioTek	bt-274751	https://www.thebiotek.com/product/inhibitors/bt-274751
THE BioTek	bt-288308	https://www.thebiotek.com/product/inhibitors/bt-288308
Vitas-M Laboratory	BBL028456	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL028456&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Vitas-M Laboratory	STL061087	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=STL061087&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
eNovation Chemicals	D131877	https://www.enovationchem.com/ProductDetails.asp?ProductID=D131877
eNovation Chemicals	D388881	https://www.enovationchem.com/ProductDetails.asp?ProductID=D388881
eNovation Chemicals	D672996	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672996
mcule	MCULE-3049117865	https://mcule.com/MCULE-3049117865/
mcule	MCULE-9567672915	https://mcule.com/MCULE-9567672915/

PubMed

Title	Date	PubMed
RETINOPATHY DURING CHLOROQUINE THERAPY.	1961 Nov	18170732
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model.	1991 Nov-Dec	1818183
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992 Sep	1416885
Involvement of calcium signaling in the fibronectin-stimulated macrophage recognition of oxidatively damaged erythrocytes.	2001 Apr 23	11336783
Two distinct mechanisms are involved in stent thrombosis under flow conditions.	2001 Jun	11454257
Hypoxia alters the sensitivity of the L-type Ca(2+) channel to alpha-adrenergic receptor stimulation in the presence of beta-adrenergic receptor stimulation.	2001 May 25	11375273
tert-Butyl hydroperoxide-induced lipid signaling in hepatocytes: involvement of glutathione and free radicals.	2001 Sep 15	11551515
[Creutzfeldt-Jakob disease: diagnosis, incidence, prevention and treatment].	2002 Apr 20	11998351
Involvement of oxidative stress in bee venom-induced inhibition of Na+/glucose cotransporter in renal proximal tubule cells.	2002 Jul	12060098
Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions.	2002 Jul 9	12105169
Participation of the arachidonic acid cascade pathway in macrophage binding/uptake of oxidized low density lipoprotein.	2002 Jun	12081134
High glucose down-regulates angiotensin II binding via the PKC-MAPK-cPLA2 signal cascade in renal proximal tubule cells.	2002 Mar	11849446
Regulation of reactive oxygen species and stress fiber formation by calpeptin in Swiss 3T3 fibroblasts.	2002 Mar	11812648
Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions.	2002 Oct 15	12351386
Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation.	2002 Sep	12235523
Effects of cholesterol on dye leakage induced by multidrug-resistance modulators from anionic liposomes.	2003 Jan	12554076
Effect of epinephrine on alpha-methyl-D-glucopyranoside uptake in renal proximal tubule cells.	2004	15319543
Assessment of platelet activation in myeloproliferative disorders with complementary techniques.	2004 Apr	15060419
Oral mucosal pigmentation secondary to treatment with mepacrine, with sparing of the denture bearing area.	2004 Aug	15225957
The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage.	2004 Dec 1	15297306
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).	2004 Feb	14961162
Cyclic stretch-induced cPLA2 mediates ERK 1/2 signaling in rabbit proximal tubule cells.	2004 Feb	14717925
[Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings].	2004 Jun	15235744
Oxalate inhibits renal proximal tubule cell proliferation via oxidative stress, p38 MAPK/JNK, and cPLA2 signaling pathways.	2004 Oct	15229103
Serum ferritin elevation and acute lung injury in rats subjected to hemorrhage: reduction by mepacrine treatment.	2004 Oct-Nov	15371093
High glucose inhibits fructose uptake in renal proximal tubule cells: involvement of cAMP, PLC/PKC, p44/42 MAPK, and cPLA2.	2004 Sep	15254969
Role of contractile prostaglandins and Rho-kinase in growth factor-induced airway smooth muscle contraction.	2005 Jul 27	16048647
Blood schizontocidal activity of azithromycin and its combination with alpha/beta arteether against multi-drug resistant Plasmodium yoelii nigeriensis, a novel MDR parasite model for antimalarial screening.	2005 Sep	16178350
In vitro antiproliferative effects of neuroleptics, antimycotics and antibiotics on the human pathogens Acanthamoeba polyphaga and Naegleria fowleri.	2006 Aug	16824931
Hypoxia-induced sickness behaviour.	2006 Nov	17242471
Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.	2006 Oct 21	17072963
Oral given Mepacrine could increase the resistance to heat environment injury.	2007	17023118
Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL.	2007 Aug 15	17541981
HPA-1 polymorphism of alphaIIbbeta3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system.	2007 Feb 19	17309793
Involvement of free radicals followed by the activation of phospholipase A2 in the mechanism that underlies the combined effects of methamphetamine and morphine on subacute toxicity or lethality in mice: comparison of the therapeutic potential of fullerene, mepacrine, and cooling.	2007 Jul 17	17553606
Drug, dosage, activity, studies of antimalarials by physical methods--II.	2007 May 20	18084644
Roles of brain phosphatidylinositol-specific phospholipase C and diacylglycerol lipase in centrally administered histamine-induced adrenomedullary outflow in rats.	2007 Oct 1	17628524
Mepacrine alleviates airway hyperresponsiveness and airway inflammation in a mouse model of asthma.	2008 Jun	18442795
Plasmodium vivax trophozoites insensitive to chloroquine.	2008 May 27	18505560
Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiprotozoal activities.	2008 Nov 7	18931800
ATP-induced apoptosis involves a Ca2+-independent phospholipase A2 and 5-lipoxygenase in macrophages.	2009 Jan	18984060
Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity.	2009 Jun	18754103

Patents

Sample Use Guides

In Vivo Use Guide

Capsule: 25‐200 mg, Suppositories: 25-100 mg.

Route of Administration: Other

In Vitro Use Guide

The concentration of Quinacrine needed to reduce Candida albicans biofilm metabolic activity by 50% (sMIC50) was 256 ug/ml, and the concentration needed to reduce Candida albicans biofilm metabolic activity by 90% (sMIC90) was 1,024 ug/ml.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:12:37 GMT 2023` Edited by `admin` on `Fri Dec 15 15:12:37 GMT 2023`
Record UNII	G6242H2NAA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QUINACRINE HYDROCHLORIDE

Common Name

English

QUINACRINE HYDROCHLORIDE DIHYDRATE

Common Name

English

6-Chloro-9-[[4-(diethylamino)-1-methylbutyl]amino]-2-methoxyacridine dihydrochloride dihydrate

Systematic Name

English

NSC-757307

Code

English

QUINACRINE HCL

Common Name

English

QUINACRINE DIHYDROCHLORIDE DIHYDRATE [MI]

Common Name

English

QUINACRINE HYDROCHLORIDE [VANDF]

Common Name

English

MEPACRINE HYDROCHLORIDE

Common Name

English

(±)-6-CHLORO-9-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)-2-METHOXYACRIDINE DIHYDROCHLORIDE DIHYDRATE

Systematic Name

English

MEPACRINE HYDROCHLORIDE DIHYDRATE

Common Name

English

MEPACRINE DIHYDROCHLORIDE DIHYDRATE

Common Name

English

QUINACRINE DIHYDROCHLORIDE DIHYDRATE

Common Name

English

ATABRINE HYDROCHLORIDE

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

4184